Mihael Polymeropoulos, Vanda Pharmaceuticals CEO
Vanda's gastric drug flops in late-stage test, crashing the biotech's stock
You may remember Vanda Pharmaceuticals from its brief feud with the FDA over a partial clinical hold on gastric drug tradipitant — a fight it would …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
